{"id":474501,"date":"2021-04-10T08:33:34","date_gmt":"2021-04-10T12:33:34","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=474501"},"modified":"2021-04-10T08:33:34","modified_gmt":"2021-04-10T12:33:34","slug":"genocea-to-present-novel-preclinical-inhibigen-data-at-aacr-annual-meeting-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/genocea-to-present-novel-preclinical-inhibigen-data-at-aacr-annual-meeting-2021\/","title":{"rendered":"Genocea to Present Novel Preclinical Inhibigen\u2122 Data at AACR Annual Meeting 2021"},"content":{"rendered":"
\n

\n Pro-tumor effects detected as early as four days after Inhibigen administration<\/em>
\n \n <\/p>\n

\n Insights into Inhibigen biology may yield new therapeutic targets to address immunotherapy resistance <\/em>\n <\/p>\n

CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) — Genocea Biosciences, Inc.<\/a> (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today presented preclinical data that offers new insights into Inhibigen\u2122-associated responses and continues to underscore the detrimental impact of their inclusion in cancer immunotherapies at the\u00a0American Association for Cancer Research (AACR) Annual Meeting 2021 from\u00a0April 10-15. The findings \u2013 powered by Genocea\u2019s proprietary ATLAS\u2122\u00a0platform \u2013 further validate previous research presented at<\/a> SITC 2020 and published in<\/a>Cancer Discovery<\/em>, together revealing that the presence of an Inhibigen (antigen uniquely identifiable by ATLAS as dampening anti-tumor immune responses) in an otherwise protective immunotherapy can completely reverse the therapy\u2019s intended anti-tumor responses.<\/p>\n

The new data show that therapeutic vaccination of tumor-bearing mice with a single Inhibigen caused their tumors to hyperprogress, in contrast to a vaccine containing stimulatory antigens that protected them against tumor growth. The combination of this single Inhibigen with the otherwise-protective vaccine abrogated vaccine efficacy and returned tumor growth to levels of unvaccinated mice. The Inhibigen-associated effects included dampening of T cell immune responses as early as four days after a single dose, and a reversal of the infiltration of both lymphoid and myeloid populations into the tumor microenvironment. These data suggest that Inhibigen-specific responses not only dampen systemic immunity, but also revert tumor microenvironments to an immune-cold state \u2013 a feature of early-stage tumor growth.<\/p>\n

\u201cOur data add to a growing body of preclinical and clinical evidence confirming that\u00a0Inhibigens\u00a0are not innocent bystanders, but\u00a0rather\u00a0they\u00a0can reverse the beneficial effects of cancer immunotherapies,\u201d said Hanna Starobinets, a scientist at Genocea and lead presenter at the AACR meeting. \u201cWhile Genocea continues to exclude Inhibigens from its immunotherapy candidates, ongoing studies aim to further allow us to understand and overcome immunotherapy resistance.\u201d<\/p>\n

Genocea previously demonstrated that Inhibigen vaccination could stifle immune responses to other antigens co-formulated in a vaccine, and that the effect could not be reversed through combination therapy with immune checkpoint inhibitors (ICI). Moreover, early data<\/a> from ATLAS profiling of T cell responses in patients with cancer showed that the relative proportion of Inhibigen- and neoantigen-specific responses prior to treatment appeared to predict clinical efficacy of subsequent ICI therapy.<\/p>\n

\u201cWhile we avoid Inhibigens in our current immunotherapy candidates, our preclinical work is focused on understanding the mechanisms of Inhibigen-associated immune suppression so that we may ultimately develop new treatments that can revert the\u00a0phenotype in the context of immuno-oncology and\u00a0perhaps even\u00a0drive the phenotype in other contexts, such as autoimmune diseases,\u201d said Jessica Baker Flechtner, Chief Scientific Officer of Genocea. \u201cThis important nuance \u2013 the possibility for Inhibigens to be used for therapeutic benefit \u2013 is one that we look forward to exploring further as we continue to gain insights into their underlying biology and function.\u201d<\/p>\n

\n AACR POSTER SESSION CATEGORY: Inflammation, Immunity, and Cancer<\/strong>
\n
\n TRACK: Immunology, Clinical Research Excluding Trials<\/strong>
\n
\n
\n Poster 1762<\/strong>
\n <\/a>
\n
\n Title:<\/strong>
\n
\n Inhibigens\u2122<\/em>
\n <\/strong>
\n
\n \u00a0subvert otherwise-efficacious cancer vaccines and immunotherapies in conjunction with alterations in the tumor microenvironment<\/em>
\n <\/strong>
\n
Presenter:\u00a0Hanna Starobinets, Ph.D.,\u00a0Genocea Biosciences,\u00a0Cambridge, MA
Date:\u00a0April 10, 2021
Time:\u00a08:30 a.m.\u00a0\u2013\u00a011:59 p.m. EDT<\/p>\n

\n About Genocea Biosciences, Inc.<\/strong>
\n
Genocea\u2019s mission is to identify the right tumor targets to develop life-changing immunotherapies for people suffering from cancer. Our proprietary ATLAS\u2122 platform comprehensively profiles each patient\u2019s T cell responses to potential targets, or antigens, on that patient\u2019s tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, Inhibigens\u2122, that drive pro-tumor immune responses. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine for which we are conducting a Phase 1\/2a clinical trial and GEN-011, our adoptive T cell therapy using neoantigen-targeted peripheral cells for which we are commencing a Phase 1\/2a clinical trial. In addition to our two clinical programs, we are conducting research in several areas where we believe ATLAS could be a key tool in identifying meaningful therapies. To learn more, please visit\u00a0https:\/\/www.genocea.com<\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>
\n
\n This press release includes forward-looking statements related to GEN-009, GEN-011 and research updates within the meaning of the Private Securities Litigation Reform Act. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Genocea cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties that change over time. Applicable risks and uncertainties include those identified under the heading “Risk Factors” included in Genocea’s Annual Report on Form 10-K for the year ended December 31, 2020 and any subsequent SEC filings. These forward-looking statements speak only as of the date of this press release and Genocea assumes no duty to update forward-looking statements, except as may be required by law.<\/em>\n <\/p>\n\n\n\n\n\n
\n Investor Contact:<\/strong>\n <\/td>\n\n Media Contact:<\/strong>\n <\/td>\n<\/tr>\n
Dan Ferry<\/td>\nSarah O\u2019Connell<\/td>\n<\/tr>\n
617-430-7576<\/td>\n\n soconnell@vergescientific.com<\/a>\u00a0<\/td>\n<\/tr>\n
\n daniel@lifesciadvisors.com<\/a>\n <\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Pro-tumor effects detected as early as four days after Inhibigen administration Insights into Inhibigen biology may yield new therapeutic targets to address immunotherapy resistance CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) — Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today presented preclinical data that offers new insights into Inhibigen\u2122-associated responses and continues to underscore the detrimental impact of their inclusion in cancer immunotherapies at the\u00a0American Association for Cancer Research (AACR) Annual Meeting 2021 from\u00a0April 10-15. The findings \u2013 powered by Genocea\u2019s proprietary ATLAS\u2122\u00a0platform \u2013 further validate previous research presented at SITC 2020 and published inCancer Discovery, together revealing that the presence of an Inhibigen (antigen uniquely identifiable by ATLAS as dampening anti-tumor immune responses) in … <\/p>\n

Continue reading “Genocea to Present Novel Preclinical Inhibigen\u2122 Data at AACR Annual Meeting 2021”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-474501","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nGenocea to Present Novel Preclinical Inhibigen\u2122 Data at AACR Annual Meeting 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/genocea-to-present-novel-preclinical-inhibigen-data-at-aacr-annual-meeting-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Genocea to Present Novel Preclinical Inhibigen\u2122 Data at AACR Annual Meeting 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Pro-tumor effects detected as early as four days after Inhibigen administration Insights into Inhibigen biology may yield new therapeutic targets to address immunotherapy resistance CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) — Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today presented preclinical data that offers new insights into Inhibigen\u2122-associated responses and continues to underscore the detrimental impact of their inclusion in cancer immunotherapies at the\u00a0American Association for Cancer Research (AACR) Annual Meeting 2021 from\u00a0April 10-15. The findings \u2013 powered by Genocea\u2019s proprietary ATLAS\u2122\u00a0platform \u2013 further validate previous research presented at SITC 2020 and published inCancer Discovery, together revealing that the presence of an Inhibigen (antigen uniquely identifiable by ATLAS as dampening anti-tumor immune responses) in … Continue reading "Genocea to Present Novel Preclinical Inhibigen\u2122 Data at AACR Annual Meeting 2021"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/genocea-to-present-novel-preclinical-inhibigen-data-at-aacr-annual-meeting-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-10T12:33:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNDUzMSM0MTE0MDYwIzIwMDU1NDM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genocea-to-present-novel-preclinical-inhibigen-data-at-aacr-annual-meeting-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genocea-to-present-novel-preclinical-inhibigen-data-at-aacr-annual-meeting-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Genocea to Present Novel Preclinical Inhibigen\u2122 Data at AACR Annual Meeting 2021\",\"datePublished\":\"2021-04-10T12:33:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genocea-to-present-novel-preclinical-inhibigen-data-at-aacr-annual-meeting-2021\\\/\"},\"wordCount\":826,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genocea-to-present-novel-preclinical-inhibigen-data-at-aacr-annual-meeting-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxNDUzMSM0MTE0MDYwIzIwMDU1NDM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genocea-to-present-novel-preclinical-inhibigen-data-at-aacr-annual-meeting-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genocea-to-present-novel-preclinical-inhibigen-data-at-aacr-annual-meeting-2021\\\/\",\"name\":\"Genocea to Present Novel Preclinical Inhibigen\u2122 Data at AACR Annual Meeting 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genocea-to-present-novel-preclinical-inhibigen-data-at-aacr-annual-meeting-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genocea-to-present-novel-preclinical-inhibigen-data-at-aacr-annual-meeting-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxNDUzMSM0MTE0MDYwIzIwMDU1NDM=\",\"datePublished\":\"2021-04-10T12:33:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genocea-to-present-novel-preclinical-inhibigen-data-at-aacr-annual-meeting-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genocea-to-present-novel-preclinical-inhibigen-data-at-aacr-annual-meeting-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genocea-to-present-novel-preclinical-inhibigen-data-at-aacr-annual-meeting-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxNDUzMSM0MTE0MDYwIzIwMDU1NDM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxNDUzMSM0MTE0MDYwIzIwMDU1NDM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genocea-to-present-novel-preclinical-inhibigen-data-at-aacr-annual-meeting-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Genocea to Present Novel Preclinical Inhibigen\u2122 Data at AACR Annual Meeting 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Genocea to Present Novel Preclinical Inhibigen\u2122 Data at AACR Annual Meeting 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/genocea-to-present-novel-preclinical-inhibigen-data-at-aacr-annual-meeting-2021\/","og_locale":"en_US","og_type":"article","og_title":"Genocea to Present Novel Preclinical Inhibigen\u2122 Data at AACR Annual Meeting 2021 - Market Newsdesk","og_description":"Pro-tumor effects detected as early as four days after Inhibigen administration Insights into Inhibigen biology may yield new therapeutic targets to address immunotherapy resistance CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) — Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today presented preclinical data that offers new insights into Inhibigen\u2122-associated responses and continues to underscore the detrimental impact of their inclusion in cancer immunotherapies at the\u00a0American Association for Cancer Research (AACR) Annual Meeting 2021 from\u00a0April 10-15. The findings \u2013 powered by Genocea\u2019s proprietary ATLAS\u2122\u00a0platform \u2013 further validate previous research presented at SITC 2020 and published inCancer Discovery, together revealing that the presence of an Inhibigen (antigen uniquely identifiable by ATLAS as dampening anti-tumor immune responses) in … Continue reading \"Genocea to Present Novel Preclinical Inhibigen\u2122 Data at AACR Annual Meeting 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/genocea-to-present-novel-preclinical-inhibigen-data-at-aacr-annual-meeting-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-10T12:33:34+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNDUzMSM0MTE0MDYwIzIwMDU1NDM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genocea-to-present-novel-preclinical-inhibigen-data-at-aacr-annual-meeting-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genocea-to-present-novel-preclinical-inhibigen-data-at-aacr-annual-meeting-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Genocea to Present Novel Preclinical Inhibigen\u2122 Data at AACR Annual Meeting 2021","datePublished":"2021-04-10T12:33:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genocea-to-present-novel-preclinical-inhibigen-data-at-aacr-annual-meeting-2021\/"},"wordCount":826,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genocea-to-present-novel-preclinical-inhibigen-data-at-aacr-annual-meeting-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNDUzMSM0MTE0MDYwIzIwMDU1NDM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genocea-to-present-novel-preclinical-inhibigen-data-at-aacr-annual-meeting-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/genocea-to-present-novel-preclinical-inhibigen-data-at-aacr-annual-meeting-2021\/","name":"Genocea to Present Novel Preclinical Inhibigen\u2122 Data at AACR Annual Meeting 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genocea-to-present-novel-preclinical-inhibigen-data-at-aacr-annual-meeting-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genocea-to-present-novel-preclinical-inhibigen-data-at-aacr-annual-meeting-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNDUzMSM0MTE0MDYwIzIwMDU1NDM=","datePublished":"2021-04-10T12:33:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genocea-to-present-novel-preclinical-inhibigen-data-at-aacr-annual-meeting-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/genocea-to-present-novel-preclinical-inhibigen-data-at-aacr-annual-meeting-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genocea-to-present-novel-preclinical-inhibigen-data-at-aacr-annual-meeting-2021\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNDUzMSM0MTE0MDYwIzIwMDU1NDM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNDUzMSM0MTE0MDYwIzIwMDU1NDM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genocea-to-present-novel-preclinical-inhibigen-data-at-aacr-annual-meeting-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Genocea to Present Novel Preclinical Inhibigen\u2122 Data at AACR Annual Meeting 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/474501","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=474501"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/474501\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=474501"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=474501"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=474501"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}